Reactive oxygen species and vascular biology: Implications in human hypertension

Hypertension Research

Volumn 34, Issue 1, 2011, Pages 5-14

  Touyz, Rhian M ^a   Briones, Ana M ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

antioxidant; blood pressure; inflammation; Nox; superoxide; vascular remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; APOCYNIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVINE MONONUCLEOTIDE REDUCTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; ENZYME REGULATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; VASCULAR BIOLOGY;

BLOOD PRESSURE; BLOOD VESSELS; HUMANS; HYPERTENSION; INFLAMMATION; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 78650882643     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.201     Document Type: Review

References (189)

1. Kakar P, Lip GY. Towards understanding the aetiology and pathophysiology of human hypertension: where are we now? J Hum Hypertens 2006; 20: 833-836.
2. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005; 14: 125-131.
3. Harris DM, Cohn HI, Pesant S, Eckhart AD. GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond) 2008; 115: 79-89.
4. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H938-H944.
5. Sedeek M, Hébert RL, Kennedy CR, Burns KD, Touyz RM. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009; 18: 122-127.
6. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-352.
7. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
8. Mueller CF, Laude K, McNally JS, Harrison DG. Redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 2005; 25: 274-278.
9. Harrison DG, Widder J, Grumbach I, Chen W, Weber M, Searles C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006; 259: 351-363.
10. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593.
11. Landmesser U, Harrison DG, Drexler H. Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006; 62: 13-19.
12. Romanowski A, Murray IR, Huston MJ. Effects of hydrogen peroxide on normal and hypertensive rats. Pharm Acta Helv 1960; 35: 354-357.
13. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NAD(P)H oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
14. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC, Díez J. Vascular NADH/NAD(P)H oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-1061.
15. Akasaki T, Ohya Y, Kuroda J, Eto K, Abe I, Sumimoto H, Iida M. Increased expression of gp91phox homologues of NAD(P)H oxidase in the aortic media during chronic hypertension: involvement of the renin-angiotensin system. Hypertens Res 2006; 29: 813-820.
16. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. NAD(P)H oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004; 109: 1795-1801.
17. Kagota S, Tada Y, Kubota Y, Nejime N, Yamaguchi Y, Nakamura K, Kunitomo M, Shinozuka K. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/ NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovasc Pharmacol 2007; 50: 677-685.
18. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40: 511-515.
19. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22: 535-542.
20. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40: 866-871.
21. Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, Lerman LO, Lerman A. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 2008; 51: 127-133.
22. Franco MC, Kawamoto EM, Gorjão R, Rastelli VM, Curi R, Scavone C, Sawaya AL, Fortes ZB, Sesso R. Biomarkers of oxidative stress and antioxidant status in children born small for gestational age: evidence of lipid peroxidation. Pediatr Res 2007; 62: 204-208.
23. Cottone S, Mulè G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadalà A, Nardi E, Cusimano P, Cerasola G. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 2009; 24: 497-503.
24. Mistry HD, Wilson V, Ramsay MM, Symonds ME, Broughton Pipkin F. Reduced selenium concentrations and glutathione peroxidase activity in preeclamptic pregnancies. Hypertension 2008; 52: 881-888.
25. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney Jr JF, Vita JA. Treatment of hypertension with ascorbic acid. Lancet 1999; 354: 2048-2049.
26. Duffy SJ, Gokce N, Holbrook M, Hunter LM, Biegelsen ES, Huang A, Keaney Jr JF, Vita JA. Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. Am J Physiol Heart Circ Physiol 2001; 280: H528-H534.
27. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clin Sci (Lond) 2002; 103: 339-344.
28. Hatzitolios A, Iliadis F, Katsiki N, Baltatzi M. Is the anti-hypertensive effect of dietary supplements via aldehydes reduction evidence based? A systematic review. Clin Exp Hypertens 2008; 30: 628-639.
29. Wray DW, Uberoi A, Lawrenson L, Bailey DM, Richardson RS. Oral antioxidants and cardiovascular health in the exercise-trained and untrained elderly: a radically different outcome. Clin Sci (Lond) 2009; 116: 433-441.
30. Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol Chem 1997; 272: 18515-18517.
31. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, Weyand C, Gordon FJ, Harrison DG. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010; 55: 277-283.
32. Nistala R, Wei Y, Sowers JR, Whaley-Connell A. Renin-angiotensin- aldosterone system-mediated redox effects in chronic kidney disease. Transl Res 2009; 153: 102-113.
33. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med 2005; 26: 340-352.
34. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367-1373.
35. Mendez JI, Nicholson WJ, Taylor WR. SOD isoforms and signaling in blood vessels: evidence for the importance of ROS compartmentalization. Arterioscler Thromb Vasc Biol 2005; 25: 887-888.
36. Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill PS, Aslam S, Wang X, Ji H, Sandberg K, Jose P, Wilcox CS. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension 2006; 48: 934-941. (Pubitemid 44611008)
37. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreduc-tase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 2008; 275: 3278-3289. (Pubitemid 351813552)
38. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413.
39. Adlam D, Bendall JK, De Bono JP, Alp NJ, Khoo J, Nicoli T, Yokoyama M, Kawashima S, Channon KM. Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice. Exp Physiol 2007; 92: 119-126.
40. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol 2006; 26: 2439-2444.
41. Liu Y, Zhao H, Li H, Kalyanaraman B, Nicolosi AC, Gutterman DD. Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res 2003; 93: 573-580.
42. DeLano FA, Parks DA, Ruedi JM, Babior BM, Schmid-Schonbein GW. Microvascular display of xanthine oxidase and NAD(P)H oxidase in the spontaneously hypertensive rat. Microcirculation 2006; 13: 551-566.
43. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-932.
44. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-1209.
45. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 2004; 37: 755-767.
46. James AM, Murphy MP. How mitochondrial damage affects cell function. J Biomed Sci 2002; 9: 475-487.
47. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185-198.
48. Wosniak J, Santos CX, Kowaltowski AJ, Laurindo FR. Cross-talk between mitochondria and NAD(P)H oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal 2009; 11: 1265-1278.
49. Nozoe M, Hirooka Y, Koga Y, Araki S, Konno S, Kishi T, Ide T, Sunagawa K. Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. J Hypertens 2008; 26: 2176-2184.
50. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors Can J Physiol Pharmacol 2007; 85: 97-104.
51. Zhang GX, Lu XM, Kimura S, Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res 2007; 76: 204-212.
52. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. Am J Physiol 1990; 258: C755-C786.
53. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-176.
54. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102: 488-496.
55. Ungvari Z, Labinskyy N, Gupte S, Chander PN, Edwards JG, Csiszar A. Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats. Am J Physiol Heart Circ Physiol 2008; 294: H2121-H2128.
56. Postnov YV, Orlov SN, Budnikov YY, Doroschuk AD, Postnov AY. Mitochondrial energy conversion disturbance with decrease in ATP production as a source of systemic arterial hypertension. Pathophysiology 2007; 14: 195-204.
57. Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R, Huang Y, Bernatchez P, Giordano FJ, Shadel G, Sessa WC, Min W. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol 2007; 170: 1108-1120.
58. Rodriguez-Iturbe B, Sepassi L, Quiroz Y, Ni Z, Wallace DC, Vaziri ND. Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence. J Appl Physiol 2007; 102: 255-260.
59. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006; 1757: 509-517.
60. De Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 2007; 27: 545-553.
61. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22: 1141-1149.
62. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) 2006; 110: 243-253.
63. Yang Q, Kim SK, Sun F, Cui J, Larson MG, Vasan RS, Levy D, Schwartz F. Maternal influence on blood pressure suggests involvement of mitochondrial DNA in the pathogenesis of hypertension: the Framingham Heart Study. J Hypertens 2007; 25: 2067-2073.
64. Rachek LI, Grishko VI, LeDoux SP, Wilson GL. Role of nitric oxide-induced mtDNA damage in mitochondrial dysfunction and apoptosis. Free Radic Biol Med 2006; 40: 754-762.
65. Puddu P, Puddu GM, Cravero E, De PS, Muscari A. The putative role of mitochondrial dysfunction in hypertension. Clin Exp Hypertens 2007; 29: 427-434.
66. Miller AA, Drummond GR, Sobey CG. Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther 2006; 111: 928-948.
67. Dworakowski R, Alom-Ruiz SP, Shah AM. NADPH oxidase-derived reactive oxygen species in the regulation of endothelial phenotype. Pharmacol Rep 2008; 60: 21-28.
68. Li JM, Shah AM. Intracellular localization and preassembly of the NAD(P)H oxidase complex in cultured endothelial cells. J Biol Chem 2002; 277: 19952-19960.
69. Babior BM. NAD(P)H oxidase. Curr Opin Immunol 2004; 16: 42-47.
70. Vignais PV. The superoxide-generating NAD(P)H oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002; 59: 1428-1459.
71. Taura M, Miyano K, Minakami R, Kamakura S, Takeya R, Sumimoto H. A region N-terminal to the tandem SH3 domain of p47phox plays a crucial role in the activation of the phagocyte NAD(P)H oxidase. Biochem J 2009; 419: 329-338.
72. Bokoch GM, Zhao T. Regulation of the phagocyte NAD(P)H oxidase by Rac GTPase. Antioxid Redox Signal 2006; 8: 1533-1548.
73. Geiszt M. NAD(P)H oxidases: new kids on the block. Cardiovasc Res 2006; 71: 289-299.
74. Cave AC, Brewer AC, Panicker AN, Ray R, Grieve DJ, Walker S, Shah AM. NAD(P)H oxidases in cardiovascular health and disease. Antiox Redox Sig 2006; 8: 691-727.
75. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, Harrison DG. Calcium-dependent NOX5 nicotin-amide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008; 52: 1803-1809.
76. Lassègue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010; 30: 653-661.
77. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11: 2409-2427.
78. Nisimoto Y, Tsubouchi R, Diebold BA, Qiao S, Ogawa H, Ohara T, Tamura M. Activation of NAD(P)H oxidase 1 in tumour colon epithelial cells. Biochem J 20081; 415: 57-65.
79. Muzaffar S, Shukla N, Bond M, Newby AC, Angelini GD, Sparatore A, Del Soldato P, Jeremy JY. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. J Vasc Res 2008; 45: 521-528.
80. Fernandes DC, Manoel AHO, Wosniak J, Laurindo FR. Protein disulfide isomerise overexpression in vascular smooth muscle cells induces spontaneous preemptive NAD(P)H oxidase activation nad Nox1 mRNA expression: effects of nitrosothiol exposure. Arch Biochem Biophys 2009; 484: 197-204.
81. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, Lassègue B, Griendling KK. Mechanisms of vascular smooth muscle NAD(P)H oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol 2009; 29: 480-487.
82. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NAD(P)H oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-274.
83. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-R297.
84. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90: 1205-1213.
85. Liu KL. Regulation of renal medullary circulation by the renin-angiotensin system in genetically hypertensive rats. Clin Exp Pharmacol Physiol 2009; 36: 455-461.
86. Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, Hintze TH, Wolin MS. Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. Am J Physiol Heart Circ Physiol 2009; 296: H1048-H1057.
87. Kawahara T, Lambeth JD. Molecular evolution of Phox-related regulatory subunits for NAD(P)H oxidase enzymes. BMC Evol Biol 2007; 7: 178-181.
88. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Görlach A. NOX2 and NOX4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 2006; 8: 1473-1484.
89. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh-Ohmi S, Igarashi K, Shibata Y, Sueishi K, Sumimoto H. superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 2005; 10: 1139-1151.
90. Chen K, Kirber MT, Xiao H, Yang Y, Keaney Jr JF. Regulation of ROS signal transduction by NAD(P)H oxidase 4 localization. J Cell Biol 2008; 181: 1129-1139.
91. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassègue B, Griendling KK. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2007; 27: 42-48.
92. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 2007; 89: 1159-1167.
93. Jagnandan D, Church JE, Banfi B, Stuehr DJ, Marrero MB, Fulton DJ. Novel mechanism of activation of NAD(P)H oxidase 5. Calcium sensitization via phosphorylation. J Biol Chem 2007; 282: 6494-6507.
94. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Lambeth D, Cao W. NAD(P)H oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J Biol Chem 2007; 282: 16244-16255.
95. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, Hess J, Pogrebniak A, Bickel C, Görlach A. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 2007; 42: 446-459.
96. Schulz E, Münzel T. NOX5, a new 'radical' player in human atherosclerosis J Am Coll Cardiol 2008; 52: 1810-1812.
97. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassègue B, Griendling KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 2008; 45: 329-335.
98. Montezano AC, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, He Y, He G, Callera GE, Krause K-H, Lambeth D, Touyz RM. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent pathways in human endothelial cells. Circ Res 2010; 106: 1363-1373.
99. Selemidis S, Sobey CG, Wingler K, Schmidt HH. Drummond GR NAD(P)H oxidases in the vasculature: molecular features, roles in disease, pharmacological inhibition. Pharmacol Ther 2008; 120: 254-291.
100. Li S, Tabar SS, Malec V, Eul BG, Klepetko W, Weissmann N, Grimminger F, Seeger W, Rose F, Hänze J. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid Redox Signal 2008; 10: 1687-1698.
101. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004; 24: 677-683.
102. Schröder K, Wandzioch K, Helmcke I, Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 2009; 29: 239-245.
103. Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, Lee RM. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 2006; 71: 363-373.
104. Takeya R, Sumimoto H. Regulation of novel superoxide-producing NAD(P)H oxidases. Antioxid Redox Signal 2006; 8: 1523-1532.
105. Ambasta RK, Schreiber JG, Janiszewski M, Busse R, Brandes RP. Noxa1 is a central component of the smooth muscle NAD(P)H oxidase in mice. Free Radic Biol Med 2006; 41: 193-201.
106. Cheng G, Lambeth JD. Alternative mRNA splice forms of NOXO1: differential tissue expression and regulation of Nox1 and Nox3. Gene 2005; 356: 118-126.
107. Ibi M, Matsuno K, Shiba D, Katsuyama M, Iwata K, Kakehi T, Nakagawa T, Sango K, Shirai Y, Yokoyama T, Kaneko S, Saito N, Yabe-Nishimura C. Reactive oxygen species derived from NOX1/NAD(P)H oxidase enhance inflammatory pain. J Neurosci 2008; 28: 9486-9494.
108. Peng YJ, Yuan G, Jacono FJ, Kumar GK, Prabhakar NR. 5-HTevokes sensory long-term facilitation of rodent carotid body via activation of NAD(P)H oxidase. J Physiol 2006; 576 (Part 1): 289-295.
109. Brandes RP, Schröder K. Differential vascular functions of Nox family NAD(P)H oxidases. Curr Opin Lipidol 2008; 19: 513-518.
110. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, Papaharalambus C, Lassègue B, Griendling KK. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 2009; 105: 249-259.
111. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NAD(P)H oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med 2009; 41: 217-225.
112. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol 2008; 28: 1511-1518.
113. Block K, Eid A, Griendling KK, Lee DY, Wittrant Y, Gorin Y. Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression. J Biol Chem 2008; 283: 24061-24076.
114. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. Hypertension 2006; 48: 473-481.
115. Sindhu RK, Ehdaie A, Farmand F, Dhaliwal KK, Nguyen T, Zhan CD, Roberts CK, Vaziri ND. Expression of catalase and glutathione peroxidase in renal insufficiency. Biochim Biophys Acta 2005; 1743: 86-92.
116. Tajima M, Kurashima Y, Sugiyama K, Ogura T, Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. Eur J Pharmacol 2009; 606: 45-49.
117. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-1101.
118. Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill PS, Aslam S, Wang X, Ji H, Sandberg K, Jose P, Wilcox CS. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension 2006; 48: 934-941. (Pubitemid 44611008)
119. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Praticò D, Harrison DG, Hsueh WA. Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 2009; 104: e42-e54.
120. Hool LC, Corry B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal 2007; 9: 409-435.
121. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003; 30: 860-866.
122. Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004; 44: 200-208.
123. Gutierrez J, Ballinger SW, Darley-Usmar VM, Landar A. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ Res 2006; 99: 924-932.
124. Cohen RA, Adachi T. Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med 2006; 16: 109-114.
125. Wolin MS, Gupte SA, Neo BH, Gao Q, Ahmad M. Oxidant-redox regulation of pulmonary vascular responses to hypoxia and nitric oxide-cGMP signaling. Cardiol Rev 2010; 18: 89-93.
126. Gao Q, Zhao X, Ahmad M, Wolin MS. Mitochondrial-derived hydrogen peroxide inhibits relaxation of bovine coronary arterial smooth muscle to hypoxia through stimulation of ERK MAP kinase. Am J Physiol Heart Circ Physiol 2009; 297: H2262-H2269.
127. Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H, Ohashi J, Yada T, Yanagihara N, Shimokawa H. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008; 205: 2053-2063.
128. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106: 1521-1530.
129. Chavez A, Miranda LF, Pichiule P, Chavez JC. Mitochondria and hypoxia-induced gene expression mediated by hypoxia-inducible factors. Ann N Y Acad Sci 2008; 1147: 312-320.
130. Feissner RF, Skalska J, Gaum WE, Sheu SS. Crosstalk signaling between mitochon-drial Ca2+ and ROS. Front Biosci 2009; 14: 1197-1218.
131. Callera GE, Montezano AC, Yogi A, Tostes RC, Touyz RM. Vascular signaling through cholesterol-rich domains: implications in hypertension. Curr Opin Nephrol Hypertens 2007; 16: 90-104.
132. Harrison DG, Gongora MC, Guzik TJ, Widder J. Oxidative stress and hypertension. JASH 2007; 1: 30-44.
133. Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogen-esis of hypertension. Curr Hypertens Rep 2006; 8: 232-241.
134. Gill PS, Wilcox CS. NAD(P)H oxidases in the kidney. Antioxid Redox Signal 2006; 8: 1597-1607.
135. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005; 289: R913-R935.
136. Nuyt AM. Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models. Clin Sci (Lond) 2008; 114: 1-17.
137. Fukai T, Ishizaka N, Rajagopalan S, Laursen JB, Capers QT, Taylor WR. p22phox mRNA expression and NAD(P)H oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997; 80: 45-51.
138. Haque MZ, Majid DS. Reduced renal responses to nitric oxide synthase inhibition in mice lacking the gene for gp91phox subunit of NAD(P)H oxidase. Am J Physiol Renal Physiol 2008; 295: F758-F764.
139. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 2006; 47: 238-244.
140. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NAD(P)H oxidase. Hypertension 2005; 45: 530-537.
141. Fortuno A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, Zalba G. Association of increased phagocytic NAD(P)H oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004; 22: 2169-2175.
142. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962.
143. Ward NC, Hodgson JM, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004; 36: 226-232.
144. Lee VM, Quinn PA, Jennings SC, Ng LL. Neutrophil activation and production of reactive oxygen species in pre-eclampsia. J Hypertens 2003; 21: 395-402.
145. Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, Tamai H, Takeshita A. Greater oxidative stress in healthy young men compared with premeno-pausal women. Arterioscler Thromb Vasc Biol 2002; 22: 438-442.
146. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, Tacconelli S, Degan M, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Santonastaso CL, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
147. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39: 777-780.
148. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36: 878-884.
149. Lacy F, O'Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998; 16: 291-303.
150. Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 296: R195-R200.
151. Van der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CD, Heine RJ, Teerlink T. Hyperglycemia and oxidative stress strengthen the association between myeloperox-idase and blood pressure. Hypertension 2010; 55: 1366-1372.
152. Fortuño A, Bidegain J, Baltanás A, Moreno MU, Montero L, Landecho MF, Beloqui O, Díez J, Zalba G. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. J Hypertens 2010; Jun: 23.
153. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 2001; 19: 1245-1254.
154. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 512-518.
155. Xaplanteris P, Vlachopoulos C, Baou K, Vassiliadou C, Dima I, Ioakeimidis N, Stefanadis C. The effect of p22(phox) -930A/G, A640G and C242T polymorphisms of NADPH oxidase on peripheral and central pressures in healthy, normotensive individuals. Hypertens Res 2010; May: 27.
156. Zalba G, San Jose G, Moreno MU, Fortuno A, Diez J. NAD(P)H oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 2005; 7: 1327-1336.
157. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114.
158. Simic DV, Mimic-Oka J, Pljesa-Ercegovac M, Savic-Radojevic A, Opacic M,
159. Caner M, Karter Y, Uzun H, Curgunlu A, Vehid S, Balci H, Yucel R, Guner I, Kutlu A, Yaldiran A, Ozturk E. Oxidative stress in human sustained and white coat hypertension. Int J Clin Pract 2006; 60: 1565-1571.
160. Mullan BA, Young IS, Fee H, McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 2002; 40: 804-809.
161. Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, Ducimetiere P, Hercberg S. Effects of long-term daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler Thromb Vasc Biol 2004; 24: 1485-1491.
162. Chen J, He J, Hamm L, Batuman V, Whelton PK. Serum antioxidant vitamins and blood pressure in the United States population. Hypertension 2002; 40: 810-816. (Pubitemid 35434899)
163. Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients Cleve Clin J Med 2004; 71: 327-334.
164. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003; 107: 926-928.
165. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events, and on diabetes: results of the HOPE study extension. HOPE/HOPE-TOO Study Investigators. Circulation 2005; 112: 1339-1346.
166. Kelly RP, Poo Yeo K, Isaac HB, LeeCY, Huang SH, Teng L, Halliwell B, WiseSD. Lack of effect of acute oral ingestion of vitamin C on oxidative stress, arterial stiffness or blood pressure in healthy subjects. Free Radic Res 2008; 42: 514-522.
167. Mishra GD, Malik NS, Paul AA, Wadsworth ME, Bolton-Smith C. Childhood and adult dietary vitamin E intake and cardiovascular risk factors in mid-life in the 1946 British birth cohort. Eur J Clin Nutr2003; 57: 1418-1425.
168. Poston L, Raijmakers M, Kelly F. Vitamin E in preeclampsia. Ann N YAcad Sci 2004; 1031: 242-248.
169. Houston MC. Nutrition and nutraceutical supplements in the treatment of hypertension. Expert Rev Cardiovasc Ther2010; 8: 821-833.
170. Widder JD, Guzik TJ, Mueller CF, Clempus RE, Schmidt HH, Dikalov SI, Griendling KK, Jones DP, Harrison DG. Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol 2007; 27: 762-768.
171. Cave A. Selective targeting of NAD(P)H oxidase for cardiovascular protection. Curr Opin Pharmacol 2009; 9: 208-213.
172. Fang J, Seki T, Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev 2009; 61: 290-302.
173. Dulak J, Zagorska A, Wegiel B, Loboda A, Jozkowicz A. New strategies for cardiovascular gene therapy: regulatable pre-emptive expression of pro-angiogenic and antioxidant genes. Cell Biochem Biophys 2006; 44: 31-42.
174. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res2001; 89: 408-414.
175. Weseler AR, Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr Hypertens Rep 2010; 12: 154-161.
176. VendrovAE, Madamanchi NR, Liu XL, Molnar KC, Runge M, Szyndralewiez C, Page P, Runge MS. NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombintreated vascular smooth muscle cells and in atherosclerosis. J Biol Chem 2010; 285: 26545-26557.
177. Gupte SA. Glucose-6-phosphate dehydrogenase: a novel therapeutic target in cardiovascular diseases. Curr Opin Investig Drugs 2008; 9: 993-1000.
178. Ferri C, Grassi D. Antioxidants and beneficial microvascular effects: is this the remedy? Hypertension 2010; 55: 1310-1311.
179. Rezzani R, Porteri E, De Ciuceis C, Bonomini F, Rodella LF, Paiardi S, Boari GE, Platto C, Pilu A, Avanzi D, Rizzoni D, Agabiti Rosei E. Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 2010; 55: 1373-1380.
180. Chen S, GeY, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1 R blockade. Kidney Int 2008; 74: 1128-1138.
181. Oliveira PJ, Goncalves L, Monteiro P, Providencia LA, Moreno AJ. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr Vasc Pharmacol 2005; 3: 147-158.
182. Cifuentes ME, Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 179-186.
183. Berk BC. Novel approaches to treat oxidative stress and cardiovascular diseases. Trans Am Clin Climatol Assoc 2007; 118: 209-214.
184. Sugiura T, Kondo T, Kureishi-Bando Y, Numaguchi Y, Yoshida O, Dohi Y, Kimura G, Ueda R, Rabelink TJ, Murohara T. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension 2008; 52: 491-498.
185. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp Jr JM, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362: 1282-1291.
186. Tribble DL. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E and p-carotene. A statement for the healthcare professionals from the American Heart Association. Circulation 1999; 99: 591-595.
187. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW. Canadian hypertension education program. The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol 2010; 26: 249-258.
188. Agarwal D, Haque M, Sriramula S, Mariappan N, Pariaut R, Francis J. Role of proinflammatory cytokines and redox homeostasis in exercise-induced delayed progression of hypertension in spontaneously hypertensive rats. Hypertension 2009; 54: 1393-1400.
189. Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 2009; 29: 213-221.